Analysis of covariance modeling of variant vaccines to prototype/wild type
infection
INFECTION
In analysis of covariance (ANCOVA) models (adjusted for baseline titers, age and baseline infection status) for each stage, the day 91 GMR comparing neutralization titers with variant-containing vaccines to first generation prototype/wild-type vaccines against the ancestral D614G variant ranged from 1.01 to 1.40 for each variant vaccine within the 3 stages.In stage 1, all Omicron BA.1-containing Moderna vaccines led to a day 91 GMR